A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas

Inclusion Criteria:

• Participants ≥ 18 years of age with R/R NHL (including DLBCL [ie, DLBCL nototherwise specified (NOS) and diffuse large B-Cell lymphoma/high-grade B-Celllymphoma with MYC and BCL2 rearrangements], and FL):

• For R/R DLBCL (de novo) and FL 3b: following at least 2 prior lines of therapy (eg, first-line combination chemotherapy regimen containing rituximab,anthracycline, an alkylating agent, and steroids and at least one additionaltreatment).

• For R/R DLBCL (transformed lymphoma): following at least 2 prior lines oftherapy which must have been administered after transformation.

• For R/R FL (except for FL 3b): following at least 2 prior lines of therapy andmeeting treatment criteria at the time of enrollment based on investigator´sassessment.

• Participant must have measurable disease (defined by at least one FDG-avid lesionfor FDG-avid disease and one bi-dimensionally measurable disease on cross sectionalimaging by computed tomography or magnetic resonance imaging with at least onelesion > 1.5 cm in the transverse diameter).

• Participants must accept and follow pregnancy prevention plan.

Exclusion Criteria:

• Participants must not have an Eastern Cooperative Oncology Group (ECOG) performancestatus ≥ 2.

• Participants with an inability to comply with listed restrictions, precautions andprohibited treatments.

• Participants must not have prior CAR-T, or radiotherapy ≤ 4 weeks, systemicanticancer treatment ≤ 5 half-lives or 4 weeks, allogeneic SCT ≤ 6 months (onlyapplicable to BMS-986458 single agent or rituximab combination cohorts), orautologous SCT ≤ 3 months prior to study intervention initiation.

• In BMS-986458 + T-cell engager combination cohorts: Participants must not have prioralloSCT or solid organ transplantation, history of confirmed progressive multifocalleukoencephalopathy (PML); known or suspected history of hemophagocyticlymphohistiocytosis (HLH); known or suspected chronic active Epstein-Barr (EBV)infection.

• Participants must not have any condition, including significant acute or chronicmedical illness, active or uncontrolled infection, or the presence of laboratoryabnormalities, that places participants at unacceptable risk if participating inthis study.

• Participants must not have known or suspected central nervous system involvement.